These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone. Hesketh PJ, Gandara DR, Hesketh AM, Edelman M, Webber LM, McManus M, Hainsworth JD. Cancer J Sci Am; 1997; 3(3):180-3. PubMed ID: 9161784 [Abstract] [Full Text] [Related]
7. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. Kris MG, Pendergrass KB, Navari RM, Grote TH, Nelson AM, Thomas V, Ferguson BB, Allman DS, Pizzo BA, Baker TW, Fernando IJ, Chernoff SB. J Clin Oncol; 1997 May; 15(5):2135-8. PubMed ID: 9164228 [Abstract] [Full Text] [Related]
9. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, Martinez-Cedillo J, Erazo A, Wittreich J, Eriksson LO, Carides AD, Gertz BJ. J Clin Oncol; 2001 Mar 15; 19(6):1759-67. PubMed ID: 11251007 [Abstract] [Full Text] [Related]
10. [Recent improvements in antiemetic therapy]. Roila F, Palladino MA, Ciccarese G, Basurto C. Tumori; 1997 Mar 15; 83(2 Suppl):S3-14. PubMed ID: 9235727 [Abstract] [Full Text] [Related]
11. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research. Support Care Cancer; 2000 May 15; 8(3):229-32. PubMed ID: 10789965 [Abstract] [Full Text] [Related]
12. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. Olver I, Paska W, Depierre A, Seitz JF, Stewart DJ, Goedhals L, McQuade B, McRae J, Wilkinson JR. Ann Oncol; 1996 Nov 15; 7(9):945-52. PubMed ID: 9006746 [Abstract] [Full Text] [Related]
14. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research. Ann Oncol; 1995 Oct 15; 6(8):805-10. PubMed ID: 8589019 [Abstract] [Full Text] [Related]
15. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin. Mantovani G, Macciò A, Curreli L, Lampis B, Ghiani M, Bianchi A, Contu P. Oncol Rep; 1998 Oct 15; 5(1):273-80. PubMed ID: 9458381 [Abstract] [Full Text] [Related]
17. Oral granisetron for the prevention of acute late onset nausea and vomiting in patients treated with moderately emetogenic chemotherapy. Friedman CJ, Burris HA, Yocom K, Blackburn LM, Gruben D. Oncologist; 2000 Oct 15; 5(2):136-43. PubMed ID: 10794804 [Abstract] [Full Text] [Related]
18. Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin. Oyama K, Fushida S, Kaji M, Takeda T, Yabushita K, Nezuka H, Kinami S, Kadoya N, Takai Y, Tsukioka Y, Ohyama S, Tsuji K, Tsukada T, Kinoshita J, Fujimura T, Ohta T. Int J Clin Oncol; 2016 Jun 15; 21(3):483-90. PubMed ID: 26507140 [Abstract] [Full Text] [Related]
20. Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice. Ithimakin S, Runglodvatana K, Nimmannit A, Akewanlop C, Srimuninnimit V, Keerativitayanan N, Soparattanapaisarn N, Laocharoenkeat A. Support Care Cancer; 2012 Apr 15; 20(4):849-55. PubMed ID: 21505898 [Abstract] [Full Text] [Related] Page: [Next] [New Search]